Bausch Health, Actavis Strike Deal Over Generic Xifaxan
Bausch Health has agreed to settle all litigation with Teva-owned Actavis over the antibiotic drug Xifaxan, with the generics maker agreeing to hold off until 2028 to release a knockoff version...To view the full article, register now.
Already a subscriber? Click here to view full article